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Interleukin-13 and interferon-γ are important eﬀectors of T-helper cells. Interleukin-13 increases expression of the arachidonic
acid-metabolizing enzyme, 15-lipoxygenase-1, in a variety of cell types. 15-lipoxygenase-1 is dramatically elevated in the airways
of subjects with asthma. Studies in animals indicate that 15-lipoxygenase-1 contributes to the development of allergic airway
inﬂammation but is protective in some other forms of inﬂammation. We tested the hypothesis that the ability of interleukin-
13 and interferon-γ to counterregulate allergic airway inﬂammation was potentially mediated by counterregulation of 12/15-
lipoxygenase, the mouse ortholog of 15-lipoxygenase-1. The airways of mice were treated with interleukin-13 or interferon-γ one
daypriortoeachofthefourallergenexposures.Interleukin-13augmentedandinterferon-γ inhibitedallergicairwayinﬂammation
independently of systemic IgE and mucosal IgA responses but in association with counterregulation of 12/15-lipoxygenase.
Interleukin-13 and interferon-γ counterregulate 12/15-lipoxygenase potentially contributing to the eﬀects of these cytokines on
allergic airway inﬂammation.
1.Introduction
The T-helper (Th) type 2 cytokines, interleukin (IL)-4
and IL-13, and the Th1 cytokine, interferon (IFN)-γ,
are important eﬀectors of allergic immune responses (as
reviewed in [1]). IL-4 and IL-13 share the ability to signal
via the type 2 IL-4R (as reviewed in [2]) and the levels
of IL-4 [3]a n dI L - 1 3[ 4, 5] are increased in the airways
of subjects with asthma. Individuals with asthma have
the capacity to produce increased levels of IFN-γ [6–9].
However in response to allergen, subjects with atopic asthma
have reduced IFN-γ production as compared to atopic
nonasthmatic subjects [10] and patients with unresolved
asthma have reduced IFN-γ production as compared to
subjects with resolved asthma and control subjects [11]. In
previous studies, treatment of mouse airways with IL-13
induces eosinophilic airway inﬂammation [12–14]. IL-13 is
known to induce the arachidonic acid metabolizing enzyme
15-lipoxygenase-1 (15-LO-1) in a variety of cultured human
cells including blood monocytes [15], normal bronchial
epithelialcells[16]anddendriticcells[17].Further,blockade
of IL-4 and IL-13 signaling locally in the airway provides
signiﬁcant protection in clinical studies of asthma [18].
In contrast to the eﬀects of IL-4 and IL-13, inhalation of
IFN-γ decreases eosinophilic inﬂammation in the airways of
subjects with asthma [19] and treatment of mouse airways
with IFN-γ inhibits eosinophilic airway inﬂammation [13,
20]. IFN-γ also inhibits the IL-4-induced expression of 15-
LO-1 in cultured human monocytes [21]. Thus, the evidence
suggests that the balance of IL-13 and IFN-γ levels in the
airway is important in determining the levels of local 15-
LO-1 expression and the severity of airway inﬂammation in
asthma.
The 15-LO-1 enzyme and its mouse ortholog, 12/15-LO,
insert molecular oxygen at the 12th or 15th carbon of
arachidonic acid (AA) resulting in the generation of 12(S)-
and 15(S)-hydroxyeicosatetraenoic acid (HETE) [22]. The
15-LO-1 enzyme is normally expressed in airway epithelial
cells, eosinophils, mast cells and dendritic cells [23–27]. The
overall contribution of the enzyme and its products appear2 Mediators of Inﬂammation
to be organ and disease model dependent. For example, it
has a protective role in animal models of ocular epithelial
wound healing [28], atherosclerosis [29], arthritis [30], and
periodontal inﬂammation [31]. The protective role of 15-
LO-1 is hypothesized to be mediated by the interaction
of its products with 5-LO resulting in the generation of
potent proresolving mediators including lipoxin A4 (LXA4),
resolvin E1, and protectin D1 (as reviewed in [32]). For
example, LXA4 treatment blocks allergic pleural eosinophil
inﬂux in rats [33] and protectin D1 treatment rescues 15-
LO-1 deﬁcient cells from oxidative stress-induced apoptosis
[34]. There are some circumstances in which 15-LO-1 con-
tributes to pathology. For example, 12/15-LO overexpressing
mice develop spontaneous increases in aortic fatty streak
lesions associated with increased monocyte adhesion to
aortic endothelial cells. These atherosclerotic changes were
potentially explained by increased expression of ICAM on
aortic endothelial cells [35]. In cultured adipocytes, 12(S)-
HETE treatment induces the expression of genes encoding
proinﬂammatorycytokines[36].I nmousemodelsofallergic
asthma,theoverallroleof12/15-LOappearstobeproinﬂam-
matory whether elicited by allergen alone [37, 38] or by the
combination of allergen and double-stranded RNA [39].
Clinical studies suggest that 15-LO-1 is important in
asthma.Ascomparedtohealthycontrolsubjectsandsubjects
with mild to moderate asthma, the expression and activity
of 15-LO-1 is dramatically elevated in epithelial cells and
inﬂammatory cells in the airways of individuals with severe
asthma [40]. A member of our group previously reported
that as compared to healthy control subjects, the levels of
15-LO-1 transcripts are slightly elevated in airway epithelial
cells from individuals with mild and stable asthma [41]. As
compared to nonsevere asthmatics, individuals with severe
asthma had decreases of 15-LO-1 expression in BAL cells
andincreasesof15-LO-1inbronchialbiopsieswithdramatic
decreases of LXA4 in BAL ﬂuid [42].
Based on these observations, we sought to determine if
IL-13andIFN-γ coordinatelycounterregulateallergicairway
inﬂammation and 12/15-LO in the airways of mice. We
observed augmentation of allergic airway inﬂammation by
IL-13 and inhibition of allergic airway inﬂammation by
IFN-γ in the airways of mice. The counterregulatory eﬀects
of these cytokines on allergic airway inﬂammation were
not clearly explained by changes in systemic and mucosal
immunoglobulin responses or by changes in LXA4 levels.
However, the augmentation of allergic airway inﬂammation
by IL-13 was associated with augmentation of 12/15-LO and
the inhibition of allergic airway inﬂammation by IFN-γ was
associated with inhibition of 12/15-LO. Given that 12/15-LO
contributes to the development of allergic airway inﬂamma-
tion in mice [37, 38], the results suggest that the balance of
IL-13 and IFN-γ levels in the airway might be an important
factor that counterregulates 15-LO-1 and as a consequence,
the severity of allergic airway inﬂammation in asthma.
2.MaterialsandMethods
2.1. Mice. The experiments were approved by the North-
western University Animal Care and Use Committee and
complied with the “Guide for the care and use of laboratory
animals” published by the National Academy Press (revised
1996). C57Bl/6 female 6-7-week-old mice (Jackson Labora-
tories, Bar Harbor, Me) were evaluated.
2.2.Protocols. Miceweretreatedwith1.5%chicken-eggoval-
bumin (OVA) in 50μl phosphate-buﬀered saline (PBS) or
an equivalent volume of PBS (controls) via the intratracheal
(i.t.) route once every 4 days for a total of four treatments.
Mice received 5.0μg rmIL-13 or 5.0μg rmIFN-γ (PeproTech,
Rocky Hill, NJ) in 50μl PBS or an equivalent volume of
PBS (controls) via the i.t. route one day prior to each OVA
treatment.Tissuesampleswereharvestedfourdaysfollowing
the fourth OVA treatment.
2.3. Lung Inﬂammation. Right lungs were immersed in
10% formalyn under vacuum for 24 hours then serially
dehydrated and embedded in paraﬃn. Sections (5μm)
were stained with hematoxylin and eosin. Sections from 5
mice/groupwereanalyzedbylightmicroscopyforthedensity
of inﬂammation surrounding airways and representative
images are shown. Bronchoalveolar lavage ﬂuid (BALF)
was collected via a tracheotomy with a single aliquot of
0.9ml of PBS. The BALF cells were counted and stained for
identiﬁcation by light microscopy.
2.4. Immunoglobulins. Blood was collected into tubes after
excision of a kidney and allowed to coagulate at room
temperature for 30 minutes. Serum was collected follow-
ing separation from blood cells by centrifugation. Total
immunoglobulin (Ig)E was measured in serum that was
diluted 1:50 in PBS by means of a speciﬁc ELISA kit
(R&D systems, Minneapolis, Minn). Ova-speciﬁc IgG1 was
detectedbydirectELISAasdescribed[43].Reagentswerenot
available for Ova-speciﬁc IgG1 standard curves. Therefore,
optical density values from 4-fold serially diluted samples
were compared to estimate fold diﬀerences between groups.
Total IgA was measured in cell-free BALF without dilution
by means of a speciﬁc ELISA kit (Immunology Consultants
Laboratories, Inc, Newberg, Ore).
2.5. Metabolites. 12(S)-HETE, 15(S)-HETE (Assay Designs,
AnnArbor,Mich)andLXA4(CaymanChemical,AnnArbor,
Mich) were measured in cell-free BALF without dilution by
means of speciﬁc ELISAs
2.6. Secretory Component. Ninety-six well plates were incu-
bated overnight with cell-free BALF without dilution and
then 1:200 goat antimouse secretory component (SC;
R&D systems), followed by 1:1000 horseradish peroxidase-
conjugated donkey antigoat IgG and TMB substrate (BD
Biosciences,SanJose,Calif).Concentrationsinsampleswere
determined by means of comparison with optical density
values generated by BALF to which known amounts of rmSC
(R&Dsystems)wereadded.OVA-speciﬁcSCwasdetermined
by incubating 96-well plates overnight with 0.1% OVA,
followed by cell-free BALF diluted 1:8, followed by 1:200
goat antimouse SC (R&D systems), followed by 1:1000Mediators of Inﬂammation 3
horseradish peroxidase-conjugated donkey antigoat IgG and
TMB substrate (BD Biosciences, San Jose, Calif). Due to the
lack of puriﬁed OVA-speciﬁc SIgA to generate a standard
curve, optical density values are reported.
2.7. Transcripts. The left lungs were homogenized in Trizol
(Sigma, St Louis, Mo) and 2.0μg total RNA was converted to
cDNA by means of reverse transcription. Published primer
sequences [38] were used to detect GAPDH, IL-4, IL-5,
IL-13, IFN-γ, pIgR, and 12/15-LO transcripts by means of
the Taqman method of real-time PCR. Copy numbers were
normalized to that of GAPDH.
2.8. Statistics. The Sigma-Stat V.11 software package was
used to perform ANOVA using the all pair wise multiple
comparisons procedures (Holm-Sidak method). Means and
S E M sa r es h o w nf o r6m i c ep e rg r o u p .P-values ≤ .05 were
considered statistically signiﬁcant.
3. Results andDiscussion
Allergic control mice were generated by treatment of their
airways with PBS one day prior to each of four 1.5%
OVA treatments to their airways occurring 4 days apart
(PBS/OVA). Nonallergic control mice received PBS one day
prior to each of four PBS-treatments occurring 4 days apart
(PBS/PBS).Thesegroupsofcontrolmicewerecomparedtoa
group of mice that were treated with 5.0μgr m I L - 1 3o n ed a y
prior to each 1.5% OVA treatment (IL-13/OVA) and another
group of mice that were treated with 5.0μg rmIFN-γ one
day prior to each 1.5% OVA treatment (IFN-γ/OVA). All
measurements were made 4 days following the 4th OVA (or
PBS; controls) treatment. PBS/PBS mice (Figure 1(a))h a d
no obvious inﬂammatory inﬁltrates in their lungs. PBS/OVA
mice (Figure 1(b)) developed modest airway associated
inﬂammatory inﬁltrates in their lungs. As compared to
PBS/OVA mice, IL-13/OVA mice (Figure 1(c)) developed
dramatically more airway-associated inﬂammatory inﬁl-
trates. As compared to PBS/OVA mice, IFN-γ/OVA mice
(Figure 1(d)) developed less airway-associated inﬂammatory
inﬁltrates. We quantiﬁed the lung inﬂammation by counting
the number of macrophages, eosinophils, lymphocytes and
neutrophils in BALF (Figure 1(e)). As compared to PBS/PBS
mice, PBS/OVA mice developed signiﬁcant increases of total
cells and signiﬁcant increases of each cell type. As compared
to PBS/OVA mice, IL-13/OVA mice developed signiﬁcant
increases of total cells, signiﬁcant increases of lymphocytes,
signiﬁcant increases of neutrophils, not-quite signiﬁcant
increases of macrophages (P = .09) and not-quite signiﬁcant
increases of eosinophils (P = .07). As compared to PBS/OVA
mice, IFN-γ/OVA mice developed signiﬁcant decreases of
total cells, signiﬁcant decreases of macrophages, signiﬁcant
decreases of eosinophils, no decrease of lymphocytes and
signiﬁcant decreases of neutrophils. Overall, these results
indicate that IL-13 in the airway augments the development
of allergic airway inﬂammation in mice and IFN-γ in the
airway inhibits the development of allergic airway inﬂamma-
tion in mice.
To determine the inﬂuence of IL-13 and IFN-γ in the
airway on the 12/15-LO enzyme, we measured the levels of
its AA-derived metabolites, 12(S)-HETE (Figure 2(a))a n d
15(S)-HETE(Figure 2(b))inBALF.AscomparedtoPBS/PBS
mice, PBS/OVA mice developed signiﬁcant increases of
12(S)-HETE and no signiﬁcant increase in 15(S)-HETE. As
compared to PBS/OVA mice, IL-13/OVA mice developed sig-
niﬁcant increases of both 12(S)-HETE and 15(S)-HETE. As
compared to PBS/OVA mice, IFN-γ/OVA mice did develop
signiﬁcant decreases in 15(S)-HETE but did develop a trend
toward attenuated 12(S)-HETE levels considering that these
values were not signiﬁcantly diﬀerent from PBS/PBS mice.
To help conﬁrm these results, we measured whole lung gene
transcript levels for 12/15-LO (Figure 2(c)). As compared
to PBS/PBS mice, PBS/OVA mice developed signiﬁcant
increases of 12/15-LO transcript levels. As compared to
PBS/OVA mice, IL-13/OVA mice had no increase and IFN-
γ/OVA mice had signiﬁcant decreases of 12/15-LO transcript
levels. We attempted to detect a possible inﬂuence of IL-13
and IFN-γ in the airway on LXA4 production (Figure 2(d)).
The potent proresolving metabolite LXA4 can be generated
as a consequence of an interaction between 12/15-LO
metabolites and 5-LO. In spite of LXA4 being subject to
rapid degradation, we detected almost signiﬁcant (P = .06)
increases of LXA4 in IFN-γ/ OVA treated mice as compared
to PBS/PBS treated mice. As compared to the PBS/OVA
group, there were small trends toward increases but not
signiﬁcant changes of LXA4 levels in either the IL-13/OVA or
IFN-γ/ OVA groups. The results suggest that IL-13 and IFN-
γ counterregulate 12/15-LO in the airway. Although small
quantities of proresolving mediators can have large biologic
eﬀects, we conclude that the resolution of inﬂammation
mediated by IFN-γ in this study was not associated with
obviously increased levels of LXA4 in BALF.
As compared to wild-type mice, 12/15-LO knockout
mice have increased SIgA in their airways [38]. We investi-
gated the eﬀects of IL-13 and IFN-γ in the airway on SIgA
levels because it is a potential mediator of the eﬀects of
12/15-LO on allergic airway inﬂammation. In the process
of active epithelial-mediated IgA transport, the extracellular
domain of the polymeric immunoglobulin receptor (pIgR),
termed secretory component (SC), is cleaved at the apical
epithelialsurfaceandremainscovalentlyboundtopolymeric
(p) IgA resulting in release of SIgA into the lumen (as
reviewed in [44]). Therefore, to determine the eﬀect of IL-
13 and IFN-γ in the airway on SIgA levels, we measured
total IgA (Figure 3(a))a n dt o t a lS C( Figure 3(b))i nB A L F .
As compared to PBS/PBS mice, PBS/OVA mice developed
signiﬁcant increases of total IgA and signiﬁcant increases of
total SC. As compared to PBS/OVA mice, IL-13/OVA mice
developed signiﬁcant increases of total IgA and signiﬁcant
increases of total SC. As compared to PBS/OVA mice, IFN-
γ/OVA mice had small but signiﬁcant increases of total IgA
but did not have signiﬁcant increases of total SC. Together,
these results indicate that SIgA levels were increased by
IL-13. While total IgA was somewhat increased by IFN-γ
in the airway, this might not have reﬂected an increase of
SIgA. To help conﬁrm these results, we measured the lung
gene transcript levels for pIgR (Figure 3(c)). As compared4 Mediators of Inﬂammation
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Figure 1: Eﬀects of IL-13 and IFN-γ on allergic airway inﬂammation. Representative images (5x magniﬁcation) of lungs showing airway
associated tissue inﬂammation from PBS/PBS (a), PBS/OVA (b), IL-13/OVA (c) and IFN-γ/OVA (d) mice. Scale bars are 500μm. Levels and
types of cells in BALF (e) from PBS/PBS, PBS/OVA, IL-13/OVA and IFN-γ/OVA groups of mice. ∗P-value ≤ .05 versus PBS/PBS. †P-value
≤ .05 versus PBS/OVA.
to PBS/PBS mice, PBS/OVA mice developed signiﬁcant
increases of pIgR transcript levels. As compared to PBS/OVA
mice, IL-13/OVA mice did not develop increases of pIgR
transcripts. As compared to PBS/OVA mice, IFN-γ/OVA
mice developed signiﬁcant decreases of pIgR transcript
levels. Together with the total IgA and SC results, these data
indicatethatSIgAlevelswereincreasedbyIL-13intheairway
a n dS I g Al e v e l sw e r en o ti n c r e a s e db yI F N - γ in the airway.
Following repeated OVA exposures to the airway one
would expect that the local mucosal adaptive immune
response would result in the generation of OVA-speciﬁc
SIgA. As an indirect measurement of OVA-speciﬁc SIgA,
we detected SC that remained bound to OVA coated 96-
well plates (Figure 3(d)). As compared to PBS/PBS mice,
PBS/OVA mice developed signiﬁcant levels of SC that
remainedboundtoOVAandconsideringtheincreaseoftotal
IgA and total SC in these mice, this likely reﬂects a signiﬁcant
increase of OVA-speciﬁc SIgA. As compared to PBS/OVA
mice, IL-13/OVA mice developed signiﬁcant increases in SC
that remained bound to OVA and considering the increase
of total IgA and total SC in these mice, this likely reﬂects
a signiﬁcant increase of OVA-speciﬁc SIgA. As compared to
PBS/OVA mice, IFN-γ/OVA mice did not have signiﬁcantly
increased SC that remained bound to OVA and therefore
likely did not develop increased levels of OVA-speciﬁc SIgA.
To determine if the inﬂuence of IL-13 and IFN-γ in the
airway on allergic airway inﬂammation was possibly due
to eﬀects on allergic systemic sensitization, we measured
IgE and OVA-speciﬁc IgG1 levels in serum (Figure 4). As
compared to PBS/PBS mice, PBS/OVA mice developed sig-
niﬁcant increases of serum IgE and OVA-speciﬁc IgG1 levels.
Although small trends were present for IgE, IL-13/OVAMediators of Inﬂammation 5
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Figure 2: Eﬀects of IL-13 and IFN-γ on 12/15-LO. Levels of 12(S)-HETE (a) and 15(S)-HETE (b) and LXA4 (c) in BALF and 12/15-LO
transcripts in whole lung (d) from PBS/PBS, PBS/OVA, IL-13/OVA and IFN-γ/OVA groups of mice. ∗P-value ≤ .05 versus PBS/PBS. †P-
value ≤ .05 versus PBS/OVA.
mice did not develop signiﬁcant increases of serum IgE or
OVA-speciﬁc IgG1 levels as compared to PBS/OVA mice
and IFN-γ/OVA mice did not develop signiﬁcant decreases
of serum IgE or OVA-speciﬁc IgG1 levels as compared to
PBS/OVA mice. These results suggest that an inﬂuence of IL-
13 and IFN-γ on allergic systemic sensitization is not likely
to explain their eﬀects on allergic airway inﬂammation.
To evaluate if the inﬂuence of IL-13 and IFN-γ in the
airway on allergic airway inﬂammation was possibly due to
eﬀects on endogenous Th2 and Th1 cytokines, we measured
whole lung gene transcript levels for IL-4, IL-5, IL-13, and
IFN-γ (Figure 5). As compared to PBS/PBS mice, PBS/OVA
micedevelopedsmalltrendsbutnosigniﬁcantincreaseofIL-
4, IL-5, and IL-13 (Th2 cytokine) transcript levels. However,
PBS/OVA mice developed signiﬁcant increases of IFN-γ
(Th1 cytokine) transcript levels. Although small trends
were present, IL-13/OVA mice did not develop signiﬁcant
increases in cytokine transcripts as compared to PBS/OVA
mice and IFN-γ/OVA mice not develop signiﬁcant decreases
in cytokine transcripts as compared to PBS/OVA mice. These
results suggest that an inﬂuence of IL-13 and IFN-γ on
endogenous Th2 and Th1 cytokines is not likely to explain
their eﬀects on allergic airway inﬂammation.
In this study we observed that IL-13 in the airway
augments and IFN-γ in the airway inhibits the severity of
allergic airway inﬂammation. These results are consistent
with the results of other similarly designed studies. For
example, IL-13 delivered to the airway is suﬃcient to
induce eosinophilic airway inﬂammation [12–14]a n dI F N - γ
delivered to the airway inhibits allergic airway inﬂammation
[13, 20] in mice. Consistent with the proinﬂammatory role
of IL-13 in the airway, blockade of IL-13 exclusively in
the airway [14, 45] and IL-13 gene deletion protects mice
from allergic airway inﬂammation [46]. Consistent with the
antiinﬂammatoryroleofIFN-γ intheairway,IFN-γ receptor
gene deletion augments allergic airway inﬂammation [47]
and systemic treatment of mice with an IFN-γ expressing
plasmid inhibits allergic airway inﬂammation [48].6 Mediators of Inﬂammation
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Figure 3: Eﬀects of IL-13 and IFN-γ on SIgA. Levels of IgA in BALF (a), SC in BALF (b), whole lung pIgR transcripts (c) and OVA-bound
SCinBALF(d)fromPBS/PBS,PBS/OVA,IL-13/OVAandIFN-γ/OVAgroupsofmice. ∗P-value ≤ .05versusPBS/PBS. †P-value ≤ .05 versus
PBS/OVA.
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Figure 4: Eﬀects of IL-13 and IFN-γ on serum Ig levels. Levels of IgE (a) and OVA-speciﬁc IgG1 (b) in serum from PBS/PBS, PBS/OVA,
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Figure 5: Eﬀects of IL-13 and IFN-γ on Th1 and Th2 cytokine transcripts. Levels of IL-4 (a), IL-5 (b), IL-13 (c) and IFN-γ (d) whole lung
transcripts from PBS/PBS, PBS/OVA, IL-13/OVA and IFN-γ/OVA groups of mice. ∗P-value ≤ .05 versus PBS/PBS.
These results indicate that the eﬀects of IL-13 and IFN-γ
in the airway on allergic sensitization and endogenous Th2
and Th1 cytokines do not account for their eﬀects on
allergic airway inﬂammation. There are a diverse array of
mechanisms by which it is thought that IL-13 can augment
(asreviewedin[49])andIFN-γ canattenuate(asreviewedin
[50]) allergic airway inﬂammation. To the best of our knowl-
edge,theinvivoabilityofIL-13andIFN-γ tocounterregulate
12/15-LO in the airway has not been previously reported.
As compared to wild-type mice, 12/15-LO knockout mice
are protected from allergic airway inﬂammation [37, 38].
Therefore, the local counterregulation of 12/15-LO by IL-13
and IFN-γ in the airway, as observed for the ﬁrst time
in this paper, might represent an important mechanism
by which these cytokines mediate their opposing eﬀects
on the severity of allergic airway inﬂammation. However,
it is possible that the counterregulatory eﬀect of IL-13
and IFN-γ on 12/15-LO transcripts, as observed in this
study, is not a cause but rather a consequence of the
eﬀects of these cytokines on airway inﬂammation. This is
supported by the observation that inﬂammatory cells in the
airways of asthmatics [40], and human eosinophils [27]a n d
Th2-skewed human mononuclear cells [51] are rich sources
of 15-LO-1. In addition, it is possible that the location of8 Mediators of Inﬂammation
expression of human 15-LO-1 might not be equivalent to
mouse 12/15-LO (both tissue and cell type) and this might
lead to diﬀerences in their contribution to IL-13 and IFN-γ
mediated regulation of allergic airway inﬂammation.
As compared to wild-type mice, 12/15-LO knockout
mice have elevated levels of total SIgA in their airways
[38]. Based on this observation one might predict that
induction of 12/15-LO by IL-13 would result in suppression
of total SIgA. In this study we observed that IL-13 in the
airway increased 12/15-LO metabolites. However, IL-13 in
the airway unexpectedly increased total SIgA levels. The IL-
13-mediatedincreaseoftotalSIgAlevelscouldhaveoccurred
due to a relatively greater ability of IL-13 to increase SIgA by
independent mechanisms as compared to a relatively minor
compensatory role mediated by induction of 12/15-LO. It
is also possible that while deﬁciency of 12/15-LO augments
SIgA levels [38], induction of 12/15-LO does not have the
oppositeeﬀect.12/15-LOoverexpressingmiceareresistantto
the onset of atherosclerosis in association with reduced IL-17
andPGE2withincreasedprotectinD1levels[29].Additional
studies of these mice would be helpful to determine what the
eﬀect of induction of 12/15-LO by itself is on the levels of
SIgA in the airway.
In this study, we observed augmentation of allergen-
speciﬁc SIgA by IL-13 in the context of augmented allergic
airway inﬂammation. The classical view is that speciﬁc SIgA
mediates immune exclusion at mucosal surfaces (as reviewed
in [52]). Therefore one might expect that augmentation of
speciﬁc SIgA would inhibit allergic airway inﬂammation. On
the other hand, studies of cultured human eosinophils [53–
55] and clinical studies of asthmatic subjects [56]s u g g e s t
that SIgA is a potent inducer of eosinophil degranulation.
Therefore, augmentation of SIgA by IL-13 might also
be predicted to exacerbate the severity of allergic airway
inﬂammation due to release of proinﬂammatory mediators
from eosinophils. However, mouse eosinophils are more
resistanttodegranulationascomparedtohumaneosinophils
[57] and mouse cells do not express the same repertoire of
IgA receptors as compared to human cells [58]. Therefore, it
is not clear what eﬀect speciﬁc SIgA has, if any, on allergic
airway inﬂammation and this might be, at least in part, due
to some limitations of mouse modeling.
4. Conclusions
The balance of IL-13 and IFN-γ in the airway is strongly
implicated by clinical and animal studies as an important
factor that regulates the severity of allergic airway inﬂam-
mation. As compared to normal subjects and subjects with
mild to moderate asthma, 15-LO-1 is present at dramatically
elevated levels in the airways of individuals with severe
asthma [40]. In the present study, the counterregulation
of allergic airway inﬂammation by IL-13 and IFN-γ in the
airway occurred in association with the counterregulation of
12/15-LO. The protection of 12/15-LO-deﬁcient mice from
allergic airway inﬂammation suggests that 15-LO-1 is an
important pathologic mediator of airway inﬂammation in
asthma [37, 38]. Although there are likely important diﬀer-
ences between mouse 12/15-LO and human 15-LO-1 in the
context of diﬀerent inﬂammatory settings and in their ability
to mediate the production of proresolving metabolites, this
study suggests that the counterregulation of 15-LO-1 by
IL-13 and IFN-γ may represent an important mechanism by
which IL-13 and IFN-γ mediate their opposing eﬀects on the
severity of airway inﬂammation in asthma.
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